ay-25-205 and Osteosarcoma

ay-25-205 has been researched along with Osteosarcoma* in 1 studies

Other Studies

1 other study(ies) available for ay-25-205 and Osteosarcoma

Article	Year
[Luteinizing hormone-releasing hormone (LRH) agonist in the treatment of breast cancer, osteosarcoma and prostate carcinoma--analysis of 12 patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 1988, Volume: 10, Issue:1 This paper first reports the results of 12 patients with sex hormone-dependent neoplasms, including 9 women with breast cancer, 2 men with osteosarcoma and 1 man with prostate carcinoma, treated by LRH agonist, (D-Ala6, des-Gly-NH2(10))-LRH-ethylamide (LRH-A) 100-200 micrograms, IM, QD. After 15-30 days of administration, the concentrations of plasma mean estradiol, progesterone, testosterone, serum luteinizing hormone and follicle-stimulating hormone were lowered significantly in the peripheral blood of all patients, associating with improvement of the patients' general condition and reduction of the tumors and/or metastatic foci. No serious side effects were observed except vaginal irregular bleeding in isolated patients. Three patients died and the others were alive in follow-up of 4-30 months. The results suggest that LRH-A be useful in the treatment of the sex hormone-dependent tumors and worth further study. Topics: Adolescent; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fibula; Gonadotropin-Releasing Hormone; Hormones; Humans; Male; Middle Aged; Orbital Neoplasms; Osteosarcoma; Prostatic Neoplasms	1988

Article

Year

[Luteinizing hormone-releasing hormone (LRH) agonist in the treatment of breast cancer, osteosarcoma and prostate carcinoma--analysis of 12 patients].

Zhonghua zhong liu za zhi [Chinese journal of oncology], 1988, Volume: 10, Issue:1

This paper first reports the results of 12 patients with sex hormone-dependent neoplasms, including 9 women with breast cancer, 2 men with osteosarcoma and 1 man with prostate carcinoma, treated by LRH agonist, (D-Ala6, des-Gly-NH2(10))-LRH-ethylamide (LRH-A) 100-200 micrograms, IM, QD. After 15-30 days of administration, the concentrations of plasma mean estradiol, progesterone, testosterone, serum luteinizing hormone and follicle-stimulating hormone were lowered significantly in the peripheral blood of all patients, associating with improvement of the patients' general condition and reduction of the tumors and/or metastatic foci. No serious side effects were observed except vaginal irregular bleeding in isolated patients. Three patients died and the others were alive in follow-up of 4-30 months. The results suggest that LRH-A be useful in the treatment of the sex hormone-dependent tumors and worth further study.

Topics: Adolescent; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fibula; Gonadotropin-Releasing Hormone; Hormones; Humans; Male; Middle Aged; Orbital Neoplasms; Osteosarcoma; Prostatic Neoplasms

1988